Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

Margaret G. McGlynn net worth and biography

Margaret McGlynn Biography and Net Worth

Director of Vertex Pharmaceuticals

Ms. McGlynn joined our Board in 2011. Ms. McGlynn retired from Merck & Co. in 2009, where she served as President, Vaccines and Infectious Diseases and as President, Hospital and Specialty Products. During her 26-year career at Merck, she also held various leadership roles in the U.S. and globally in marketing, sales, managed care and business development. Following her retirement, Ms. McGlynn served as the President and Chief Executive Officer of the International AIDS Vaccine Initiative, a global not-for-profit organization whose mission is to ensure the development of safe, effective and accessible HIV vaccines for use throughout the world, from 2011 until 2015. Ms. McGlynn serves as a member of the Board of Directors for Amicus Therapeutics, Inc., a biopharmaceutical company, as well as a member of the Board of Directors for Novavax, Inc., a late-stage biotechnology company. She is also a member of the National Industrial Advisory Committee at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences. Ms. McGlynn holds a B.S. in Pharmacy and an M.B.A. in Marketing and an Honorary Doctorate from the State University of New York at Buffalo.

What is Margaret G. McGlynn's net worth?: The estimated net worth of Margaret G. McGlynn is at least $23.55 million as of March 5th, 2024. Ms. McGlynn owns 59,289 shares of Vertex Pharmaceuticals stock worth more than $23,553,741 as of December 22nd. This net worth evaluation does not reflect any other investments that Ms. McGlynn may own. Learn More about Margaret G. McGlynn's net worth.
How do I contact Margaret G. McGlynn?: The corporate mailing address for Ms. McGlynn and other Vertex Pharmaceuticals executives is 50 NORTHERN AVENUE, BOSTON MA, 02210. Vertex Pharmaceuticals can also be reached via phone at (617) 341-6100 and via email at [email protected]. Learn More on Margaret G. McGlynn's contact information.
Has Margaret G. McGlynn been buying or selling shares of Vertex Pharmaceuticals?: Margaret G. McGlynn has not been actively trading shares of Vertex Pharmaceuticals over the course of the past ninety days. Most recently, Margaret G. Mcglynn sold 5,000 shares of the business's stock in a transaction on Thursday, March 31st. The shares were sold at an average price of $262.27, for a transaction totalling $1,311,350.00. Following the completion of the sale, the director now directly owns 1,099 shares of the company's stock, valued at $288,234.73. Learn More on Margaret G. McGlynn's trading history.
Who are Vertex Pharmaceuticals' active insiders?: Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), E. Morrey Atkinson, III (EVP), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vertex Pharmaceuticals?: During the last year, insiders at the pharmaceutical company sold shares 23 times. They sold a total of 79,177 shares worth more than $36,823,476.56. The most recent insider tranaction occured on November, 15th when EVP David Altshuler sold 15 shares worth more than $7,178.40. Insiders at Vertex Pharmaceuticals own 0.2% of the company. Learn More about insider trades at Vertex Pharmaceuticals.
Information on this page was last updated on 11/15/2024.

Margaret G. McGlynn Insider Trading History at Vertex Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/31/2022	Sell	5,000	$262.27	$1,311,350.00	1,099
1/28/2022	Sell	5,000	$241.79	$1,208,950.00
10/22/2019	Sell	20,000	$190.00	$3,800,000.00	24,124
8/13/2019	Sell	10,000	$185.00	$1,850,000.00	14,124
3/2/2018	Sell	10,000	$170.00	$1,700,000.00	16,312
1/23/2018	Sell	20,000	$162.50	$3,250,000.00	16,217
4/6/2015	Sell	12,500	$118.36	$1,479,500.00
11/7/2012	Buy	1,000	$45.50	$45,500.00

Margaret G. McGlynn Buying and Selling Activity at Vertex Pharmaceuticals

Vertex Pharmaceuticals Company Overview

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $397.27

$386.49

$401.31

50 Day Range

MA: $470.41

$396.64

$516.74

2 Week Range

Now: $397.27

$377.85

$519.88

Volume

6,202,268 shs

Average Volume

1,238,190 shs

Market Capitalization

$102.31 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.36